	US 12,390,435 B2
	Electrophiles and electrophile pro-drugs as RAD51 inhibitors
Bruce A. Freeman, Pittsburgh, PA (US); Carola Neumann, Pittsburgh, PA (US); and Francisco J. Schopfer, Pittsburgh, PA (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Appl. No. 17/290,963
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
PCT Filed Nov. 14, 2019, PCT No. PCT/US2019/061474 § 371(c)(1), (2) Date May 3, 2021, PCT Pub. No. WO2020/102529, PCT Pub. Date May 22, 2020.
Claims priority of provisional application 62/767,424, filed on Nov. 14, 2018.
Prior Publication US 2022/0040134 A1, Feb. 10, 2022
Int. Cl. A61K 31/201 (2006.01); A61K 31/231 (2006.01); A61K 31/4184 (2006.01); A61K 31/454 (2006.01); A61K 31/4745 (2006.01); A61K 31/502 (2006.01); A61K 31/5025 (2006.01); A61K 31/55 (2006.01); A61K 31/704 (2006.01); A61K 33/243 (2019.01); A61P 35/00 (2006.01); C07C 205/50 (2006.01)

CPC A61K 31/201 (2013.01) [A61K 31/231 (2013.01); A61K 31/4184 (2013.01); A61K 31/454 (2013.01); A61K 31/4745 (2013.01); A61K 31/502 (2013.01); A61K 31/5025 (2013.01); A61K 31/55 (2013.01); A61K 31/704 (2013.01); A61K 33/243 (2019.01); A61P 35/00 (2018.01); C07C 205/50 (2013.01)]

57 Claims

1. A method comprising co-administering to a subject having cancer, suspected of having cancer, at risk of developing cancer, or in cancer remission:

a therapeutically effective amount of at least one compound (a) selected from (a)(i) a nitroalkene fatty acid, (a)(ii) an unsaturated fatty acid having an electron withdrawing group, a leaving group, and a carbon-carbon double bond disposed between the electron withdrawing group and the leaving group, (a)(iii) a thiolated nitro fatty acid, or (a)(iv) a dicarboxylic acid compound containing an electron withdrawing group; and

a therapeutically effective amount of at least one anti-neoplastic agent (b),

wherein the cancer is a cancer with etiology of defects in DNA repair genes, a cancer with a high rate of spontaneous genomic instability, a cancer that is treated with DNA damaging agent(s), or a cancer that is treated with a combination of DNA damaging agent(s) with immunotherapy.